Olsen Jørgen H, Tangerud Karina, Wermuth Lene, Frederiksen Kirsten, Friis Søren
Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark.
Mov Disord. 2007 Jul 15;22(9):1252-7. doi: 10.1002/mds.21397.
A large follow-up study in Denmark of 14,088 patients in whom Parkinson's disease was diagnosed at hospital showed a twofold higher incidence of malignant melanoma in these patients than in the general population. In a nested case-control study of 45 patients with malignant melanoma, 97 patients with nonmelanoma skin cancer, and 172 control subjects, we investigated the hypothesis that treatment with levodopa increases the risk for skin cancer. Information on diagnoses and treatment was retrieved from medical records. We observed a significant fourfold to fivefold increase in the risk for malignant melanoma in a subgroup of patients with a probable diagnosis of idiopathic Parkinson's disease as compared with other patients. There was apparently no effect of levodopa on the risk for malignant melanoma as indicated by an odds ratio of 1.0 (95% confidence interval, 0.8-1.3) per 1,000 g cumulative intake of the drug. We conclude that the increased rate of malignant melanoma observed in patients treated at hospital for Parkinson's disease is restricted to those with idiopathic Parkinson's disease, however, unrelated to the treatment with levodopa.
丹麦一项针对14088名在医院被诊断为帕金森病患者的大型随访研究表明，这些患者中恶性黑色素瘤的发病率是普通人群的两倍。在一项对45例恶性黑色素瘤患者、97例非黑色素瘤皮肤癌患者和172名对照者的巢式病例对照研究中，我们调查了左旋多巴治疗会增加皮肤癌风险这一假设。从医疗记录中获取了诊断和治疗信息。我们观察到，与其他患者相比，可能诊断为特发性帕金森病的患者亚组中，恶性黑色素瘤风险显著增加了四倍至五倍。每累积摄入1000克该药物，左旋多巴对恶性黑色素瘤风险的比值比为1.0（95%置信区间为0.8 - 1.3），这表明左旋多巴显然对恶性黑色素瘤风险没有影响。我们得出结论，在医院接受治疗的帕金森病患者中观察到的恶性黑色素瘤发病率增加仅限于特发性帕金森病患者，然而，这与左旋多巴治疗无关。
